APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation

The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation will be asked to participate in the therapeutic part of this study.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Pancreatic Cancer
• Age: Between 18 Years - 99 Years
• Gender: All